NCT07039760 2026-03-11
Asciminib With or Without Sildenafil for Brain Tumors
Washington University School of Medicine
Phase EARLY_PHASE1 Not yet recruiting
Clinical Trials
10 trialsNCT06629584 2026-02-17
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05143840 2026-01-22
ALERTCML
Augusta University
Phase 2 Recruiting
NCT06308588 2026-01-14
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT07136428 2025-12-19
ASCENdANT
Duke University
Phase 1/2 Not yet recruiting
NCT03595917 2025-11-04
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT04838041 2025-07-30
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Medical College of Wisconsin
Phase 2 Recruiting
NCT06409936 2025-07-08
PEARL
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Recruiting
NCT05413915 2025-05-21
Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML
Sir Mortimer B. Davis - Jewish General Hospital
Phase 3 Active not recruiting
NCT03906292 2025-03-10
CMLXI
University of Jena
Phase 2 Active not recruiting